EGFR and lung carcinoma: In addition, the prevalence of EGFR mutations and TP53 mutations were 21.7% (13/60) and 1.7% (1/60), respectively, indicating that EGFR mutation is an earlier event than TP53 mutation, although both of them are early events in lung cancer [25].